AstraZeneca PLC (NASDAQ:AZN) Q2 2021 Earnings Conference Call July 29, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, BioPharmaceuticals Business Unit Marc Dunoyer - Executive Director and Chief Financial Officer Mene Pangalos - EVP, BioPharmaceuticals R&D Susan Galbraith - EVP, Oncology R&D Leon Wang - EVP, China and the Emerging Markets Aradhana Sarin - Chief Financial Officer elect Confe ...

AstraZeneca PLC (NASDAQ:AZN) Q1 2021 Earnings Conference Call April 30, 2021 6:45 AM ET Company Participants Pascal Soriot - ED and CEO Dave Fredrickson - EVP, Oncology Business Unit Ruud Dobber - EVP, Biopharmaceuticals Business Unit Marc Dunoyer - ED and CFO Mene Pangalos - EVP, Biopharmaceuticals R&D Susan Galbraith - Oncology R&D Cristian Massacesi - SVP, Late-Stage Oncology R&D Leon Wang - EVP, International and China President Conference Call Participants Peter Welford - Jefferies Tim Anderson - Wolfe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

AstraZeneca PLC (NASDAQ:AZN) Q4 2020 Earnings Conference Call February 11, 2021 6:45 AM ET Company Participants Pascal Soriot - Executive Director and Chief Executive Officer Dave Fredrickson - Executive Vice President, Oncology Business Unit Ruud Dobber - Executive Vice President, Biopharmaceuticals Business Unit Marc Dunoyer - Executive Director and Chief Financial Officer Mene Pangalos - Executive Vice President, Biopharmaceuticals R&D Pam Cheng - Executive Vice President, Operations and IT Leon Wang - E ...

Key Points Industry/Company Involved - **AstraZeneca PLC (NASDAQ:AZN)**: A global biopharmaceutical company focused on oncology, cardiovascular, renal metabolism, respiratory disease, and immunology. - **Alexion**: A global leader in immune-mediated rare diseases, known for its product Soliris and Ultomiris. Core Points and Arguments - **Strategic Merger**: AstraZeneca's acquisition of Alexion aims to accelerate its strategic and financial development, expand its immunology presence, and leverage Alexion's expertise in rare diseases. - **Scientific Synergy**: The merger combines AstraZeneca's precision medicine capabilities with Alexion's expertise in the complement system, creating opportunities for innovative drug development. - **Financial Benefits**: The transaction is expected to enhance profitability, cash flow, and debt deleveraging, with a goal of increasing the dividend and maintaining a strong investment-grade credit rating. - **Revenue Growth**: The combined company is projected to achieve double-digit revenue growth through 2025, driven by strong pipeline development and sales synergies in emerging markets, particularly China. Other Important Points - **Pipeline**: AstraZeneca has a robust pipeline with 17 Phase III medicines and life cycle projects, focusing on oncology, immunology, and other therapeutic areas. - **Alexion Pipeline**: Alexion's pipeline includes 11 molecules and 20 clinical studies across various indications, including rare diseases and neurology. - **Geographic Complementarity**: AstraZeneca has a strong presence in emerging markets, particularly China, which will support the expansion of Alexion's products in these regions. - **Cultural Alignment**: Both companies share a common culture of belief in science, innovation, and patient-centricity, which is expected to facilitate a smooth integration. - **Integration**: The integration is expected to be relatively straightforward, with limited disruption to existing teams and operations. References - [1]: AstraZeneca to acquire Alexion Conference Call December 12, 2020 9:00 AM ET - [2]: Company Participants - [3]: Conference Call Participants - [4]: Pascal Soriot - [5]: Pascal Soriot - [6]: Pascal Soriot - [7]: Pascal Soriot - [8]: Pascal Soriot - [9]: Pascal Soriot - [10]: Pascal Soriot - [11]: Pascal Soriot - [12]: Pascal Soriot - [13]: Pascal Soriot - [14]: Pascal Soriot - [15]: Pascal Soriot - [16]: Marc Dunoyer - [17]: Marc Dunoyer - [18]: Marc Dunoyer - [19]: Marc Dunoyer - [20]: Marc Dunoyer - [21]: Marc Dunoyer - [22]: Marc Dunoyer - [23]: Marc Dunoyer - [24]: Marc Dunoyer - [25]: Marc Dunoyer - [26]: Marc Dunoyer - [27]: Marc Dunoyer - [28]: Marc Dunoyer - [29]: Marc Dunoyer - [30]: Marc Dunoyer - [31]: Marc Dunoyer - [32]: Marc Dunoyer - [33]: Marc Dunoyer - [34]: Marc Dunoyer - [35]: Pascal Soriot - [36]: Pascal Soriot - [37]: Pascal Soriot - [38]: Question-and-Answer Session - [39]: Pascal Soriot - [40]: Marc Dunoyer - [41]: Pascal Soriot - [42]: Marc Dunoyer - [43]: Marc Dunoyer - [44]: Pascal Soriot - [45]: Marc Dunoyer - [46]: Marc Dunoyer - [47]: Pascal Soriot - [48]: James Gordon - [49]: Pascal Soriot - [50]: Marc Dunoyer - [51]: Pascal Soriot - [52]: Marc Dunoyer - [53]: Pascal Soriot - [54]: Andrew Baum - [55]: Pascal Soriot - [56]: Ludwig Hantson - [57]: Pascal Soriot - [58]: Ludwig Hantson - [59]: Ludwig Hantson - [60]: Ludwig Hantson - [61]: Ludwig Hantson - [62]: Pascal Soriot - [63]: Ludwig Hantson - [64]: Ludwig Hantson - [65]: Pascal Soriot - [66]: Marc Dunoyer - [67]: Pascal Soriot - [68]: Emmanuel Papadakis - [69]: Marc Dunoyer - [70]: Pascal Soriot - [71]: Marc Dunoyer - [72]: Pascal Soriot - [73]: Marc Dunoyer - [74]: Pascal Soriot - [75]: Marc Dunoyer - [76]: Pascal Soriot - [77]: Marc Dunoyer - [78]: Marc Dunoyer - [79]: Pascal Soriot - [80]: Marc Dunoyer - [81]: Pascal Soriot - [82]: Tim Anderson - [83]: Marc Dunoyer - [84]: Marc Dunoyer - [85]: Pascal Soriot - [86]: Marc Dunoyer - [87]: Pascal Soriot - [88]: Marc Dunoyer - [89]: Mene Pangalos - [90]: Pascal Soriot - [91]: Mene Pangalos - [92]: Marc Dunoyer - [93]: Pascal Soriot - [94]: Marc Dunoyer - [95]: Pascal Soriot - [96]: Marc Dunoyer - [97]: Pascal Soriot - [98]: Pascal Soriot - [99]: Mene Pangalos - [100]: Marc Dunoyer - [101]: Pascal Soriot - [102]: Ludwig Hantson - [103]: Pascal Soriot - [104]: Marc Dunoyer - [105]: Ludwig Hantson - [106]: Aradhana Sarin - [107]: Pascal Soriot - [108]: Marc Dunoyer - [109]: Pascal Soriot - [110]: Pascal Soriot - [111]: Ludwig Hantson - [112]: Pascal Soriot - [113]: Ludwig Hantson - [114]: Ludwig Hantson - [115]: Pascal Soriot

AstraZeneca PLC (NASDAQ:AZN) Q3 2020 Earnings Conference Call November 5, 2020 6:45 AM ET Company Participants Pascal Soriot – Chief Executive Officer Dave Fredrickson – Executive Vice President of the Oncology Business Unit Ruud Dobber – Executive Vice President of the Biopharmaceuticals Business Unit Marc Dunoyer – Executive Director and Chief Financial Officer Mene Pangalos – Executive Vice President of the Biopharmaceuticals R&D Group Jose Baselga – Executive Vice President of Oncology R&D Pam Cheng – E ...